No Data
No Data
Zai Lab to Announce Mid-Year 2024 Financial Results
The board of directors of Zai Lab (09688.HK) will review the interim results on August 7th.
On July 25, GeLongHui reported that the board of directors audit committee of Zai Lab (09688.HK) will review and approve the unaudited interim performance of the company and its subsidiaries for three and six months ending June 30, 2024, prepared in accordance with US GAAP and applicable rules of the US Securities and Exchange Commission on Tuesday, August 6, 2024 (Eastern Time in the United States) / Wednesday, August 7, 2024 (Hong Kong Time) and publish it.
ZAI LAB: Notice of Audit Committee Action and Date of Publication of 2024 Interim Results Announcement
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
Hong Kong stocks anomaly | Zai Lab (09688) rose more than 3% again. Recently, it announced that its Egamod subcutaneous injection was approved domestically in collaboration with Argenx.
Zai Lab (09688) rose more than 3% again. As of press time, it rose 3.50% to HKD 14.78, with a turnover of HKD 9.3122 million.
No Data